Decreased use of antidepressants in youth after US Food and Drug Administration black box warning

Psychiatry

Volumn 6, Issue 10, 2009, Pages 30-34

  Singh, Tanvir ^a   Prakash, Ashwin ^a   Rais, Theodore ^a   Kumari, Neeta ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

Adolescent; Antidepressant; Anxiety; Black box warning; Child; Depression; FDA; Suicidality; US Food and Drug Administration

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; CHILD; CHILD PSYCHIATRY; DEPRESSION; DISEASE ASSOCIATION; DRUG INFORMATION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENTAL DISEASE; MENTAL HEALTH CARE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SUICIDAL BEHAVIOR; UNITED STATES;

EID: 77649226200     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. US Food and Drug Administration. FDA Talk Paper: FDA statement regarding the antidepressant Paxil for pediatric population. June 19, 2003. http://www.ahrp.org/infomail/0603/19a.php. Accessed October 20, 2009.
2. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRI's. Am J Psychiatry. 2007;164:884-891.
3. US Food and Drug Administration. Suicidality in pediatric clinical trials of antidepressant drugs: comparison between previous analyses and Colombia University classification. August 16, 2004. http://docs.google.com/gview?a= v&q=cache:qguCfTqvH4J: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1- 11-TAB09a-Mosholder-review.pdf+FDA+meta-analysis+% 28Hammad,+2004%29&hl= en&gl=us&sig=AFQjCNFXB8sF55xr779vjOTfnkmPiaY0Ug. Accessed October 20, 2009.
4. Medco Health Solutions, Inc. FDA warning on pediatric antidepressants results in significant reduction in use. http://medco.mediaroom.com/index.php?s= 43&item=70. Accessed October 20, 2009.
5. Harris G. Study finds less youth antidepressant use. September 21, 2004. http://www.nytimes.com/2004/09/21/business/21drug.html?ex=1169614800&en= 83960e 4e3bdeff4a&ei=5070#. Accessed October 20, 2009.
6. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64:466-472.
7. Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and nonfatal self harm of regulatory action against the use of SSRI in under 18s in the United Kingdom: ecological study. BMJ. 2008;336:542-545.
8. Hammad TA, Laughern T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332-339.
9. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41-47.
10. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003;60:978-982.
11. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of early adolescent suicide. Am Gen Psychiatry. 2006;163:1898-1904.
12. Gibbons R, Brown CH, Hur K, et al. Early evidence on the effects of regulators suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164:1356-1363.
13. Olfson M, Shaffer D. SSRI prescriptions and rate of suicide. Am J Psychiatry. 2007;164:1907-1908.
14. Bhatia SK, Rezac AJ, Vitiello B, et al. Antidepressant prescribing practices for the treatment of children and adolescents. Child Adolesc Psychopharmacol. 2008;18:70-80.
15. Rosack J. New data show decline in antidepressant prescribing. Psychiatr News. 2005;40:17:39.
16. Strong C. FDA black box warning on antidepressants creates concerns for clinicians. Neuropsychiatry Rev. 2004;5(9):1.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press Inc., 2000.
18. US Food and Drug Administration. Class suicidality labeling language for antidepressant. http://google2.fda.gov/search?q=cache:DovUsS4CPvQJ:www. accessdata.fda.gov/drugsatfda-docs/label/2005/020415s018,021208s009lbl. pdf+risk+of+suicidality%E2%80%9D+labeling+language+for+antidepressants& client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output= xml-no-dtd&ie=UTF-8&access=p&oe=UTF-8. Accessed October 20, 2009.
19. Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressant: a key issue in the prevention of suicide: an analysis of 5,281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand. 1997;96:94-100.
20. Isometsa E, Henriksson M, Heikkinen M, et al. Suicide and the use of antidepressants: drug treatment of depression is inadequate (letter). BMJ. 1994;308:915.
21. Oquendo MA, Malone KM, Ellis SP, et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry. 1999;156:190-194.